US-based digital health technology developer Biolinq closed a $10m series A round today led by M Ventures, the corporate venturing arm of Merck.
Hikma Ventures, the investment division of pharmaceutical firm Hikma, also contributed funds, as did Grey Sky Venture Partners, Three Leaf Ventures, LifeSci Venture Partners and assorted individual investors.
Founded in 2012, Biolinq has developed a wirelessly-enabled biosensor patch. Its first product exploiting the technology is a minimally-invasive device that allows diabetes sufferers to continuously monitor their blood…